company background image
PTCT

PTC Therapeutics NasdaqGS:PTCT Stock Report

Last Price

US$42.06

Market Cap

US$3.0b

7D

5.8%

1Y

18.9%

Updated

04 Dec, 2022

Data

Company Financials +
PTCT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health1/6
Dividends0/6

PTCT Stock Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.

PTC Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PTC Therapeutics
Historical stock prices
Current Share PriceUS$42.06
52 Week HighUS$55.58
52 Week LowUS$25.01
Beta0.43
1 Month Change16.06%
3 Month Change-18.93%
1 Year Change18.95%
3 Year Change-14.51%
5 Year Change151.86%
Change since IPO155.06%

Recent News & Updates

Recent updates

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27
Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

Feb 09
Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Dec 27
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Therapeutics (NASDAQ:PTCT) Use Debt?

Sep 30
Health Check: How Prudently Does Therapeutics (NASDAQ:PTCT) Use Debt?

Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Sep 09
Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

We Think Some Shareholders May Hesitate To Increase PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Compensation

Jun 02
We Think Some Shareholders May Hesitate To Increase PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Compensation

Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

May 07
Estimating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Is Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load?

Mar 24
Is Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load?

When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable?

Feb 26
When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable?

The Therapeutics (NASDAQ:PTCT) Share Price Has Gained 172%, So Why Not Pay It Some Attention?

Feb 05
The Therapeutics (NASDAQ:PTCT) Share Price Has Gained 172%, So Why Not Pay It Some Attention?

Calculating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Jan 15
Calculating The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)

Did PTC Therapeutics, Inc. (NASDAQ:PTCT) Insiders Buy Up More Shares?

Dec 25
Did PTC Therapeutics, Inc. (NASDAQ:PTCT) Insiders Buy Up More Shares?

Does Therapeutics (NASDAQ:PTCT) Have A Healthy Balance Sheet?

Dec 04
Does Therapeutics (NASDAQ:PTCT) Have A Healthy Balance Sheet?

Shareholder Returns

PTCTUS BiotechsUS Market
7D5.8%4.2%1.5%
1Y18.9%-7.4%-14.9%

Return vs Industry: PTCT exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: PTCT exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is PTCT's price volatile compared to industry and market?
PTCT volatility
PTCT Average Weekly Movement7.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: PTCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PTCT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,172Stuart Peltzhttps://www.ptcbio.com

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.

PTC Therapeutics, Inc. Fundamentals Summary

How do PTC Therapeutics's earnings and revenue compare to its market cap?
PTCT fundamental statistics
Market CapUS$3.02b
Earnings (TTM)-US$531.39m
Revenue (TTM)US$696.62m

4.3x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTCT income statement (TTM)
RevenueUS$696.62m
Cost of RevenueUS$671.67m
Gross ProfitUS$24.95m
Other ExpensesUS$556.34m
Earnings-US$531.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.39
Gross Margin3.58%
Net Profit Margin-76.28%
Debt/Equity Ratio-124.6%

How did PTCT perform over the long term?

See historical performance and comparison